Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Viatris Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.29, while Viatris Inc trades at $16.11 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals.
| FNGU | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $17.86 |
52-Week Low | $13.73 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU (MicroSectors FANG+ 3X Leveraged ETN) trades at $32.45, down 3.71% today, reflecting the inherent volatility of leveraged products. Technical indicators show a bullish moving average trend but neutral oscillators, with RSI levels suggesting overbought conditions. Recent news highlights significant downside volatility, including a 16% single-session drop on June 5, 2026, underscoring the risks of 3x leverage on tech stocks.
The outlook for FNGU remains highly speculative, driven by Nasdaq-100 volatility rather than company fundamentals. Investment opportunities exist for aggressive traders betting on tech rallies, but risks include amplified losses during market downturns and structural decay from daily rebalancing. Caution is warranted given the product's design for short-term trading.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
